老虎證券

美股詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Innate Pharma SA

2.04
+0.04502.26%
成交量：1.87萬
成交額：3.74萬
市值：1.71億
市盈率：-4.51
高：2.05
開：1.99
低：1.96
收：2.00
資料載入中...
總覽公司新聞公告
2024/09/11

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/12

SEC問詢函

Form CORRESP - Correspondence
2023/04/20

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/06

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/06

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/21

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/04

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/07/12

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/05/11

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/04/27

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/16

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/02/12

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/01/27

SEC問詢函

CORRESP [Cover] - Correspondence
2020/04/24

年度報告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/14

非美公司披露報告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
更多